Acute liver failure is associated with altered cerebral expression profiles of long non-coding RNAs. (24th August 2017)

• Record Type: Journal Article
• Authors: Silva, Vinícius R.; Secolin, Rodrigo; Vemuganti, Raghu; Lopes-Cendes, Iscia; Hazell, Alan S.
• Is Part Of: Neuroscience letters. Volume 656(2017)
• Page Start: 58
• Page End: 64
• Publication Date: 2017-08-24
• Subjects: Liver disease -- Fulminant hepatic failure -- Azoxymethane -- Hepatic encephalopathy -- Astrocyte -- Molecular signaling -- Brain edema; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2017.06.038
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: Azoxymethane-induced ALF in mice at coma stage results in differentially regulated long non-coding RNAs (lncRNAs) in the frontal cortex. Analysis revealed these lncRNAs target pathways such as cytokine receptor interaction, mitogen activated protein kinase signaling, and NF-κB signaling. FDR adjustment identified upregulated lncRNAs which may contribute to lactate production and astrocyte cytoskeletal disruption/swelling. Findings suggest an important role for lncRNAs in inflammation, the neuropathology of ALF, and in terms of the functional basis of HE. Abstract: Hepatic encephalopathy (HE) represents a serious complication of acute liver failure (ALF) in which cerebral edema leading to brainstem herniation as a result of increased intracranial hypertension is a major consequence. Long non-coding RNAs (lncRNAs) play a significant role in coordinating gene expression, with recent studies indicating an influence in the pathogenesis of several diseases. To investigate their involvement in the cerebral pathophysiology of ALF, we profiled the expression of lncRNAs in the frontal cortex of mice at coma stage following treatment with the hepatotoxin azoxymethane. Of the 35, 923 lncRNAs profiled using microarrays, 868 transcripts were found to be differentially expressed in the ALF-treated group compared to the sham control group. Of these, 382 lncRNAs were upregulated and 486 lncRNAs downregulated. Pathway analysis revealed these lncRNAs target a number of biological and molecular pathways that include cytokine–cytokine receptor interaction, the mitogen activated protein kinase signaling pathway, the insulin signaling pathway, and the nuclear factor–κB signaling pathway. False discovery rate adjustment identified 9 upregulated lncRNAs, 2 of which are associated with neuroepithelial transforming gene 1 ( NET1 ) and the monocarboxylate transporter 2 ( Slc16a7 ), potential contributors to astrocyte cytoskeletal disruption/swelling and lactate production, respectively. Our findings suggest an important role for lncRNAs in the brain in ALF in relation to inflammation, neuropathology, and in terms of the functional basis of HE. Further work on these non-coding RNAs may lead to new therapeutic approaches for the treatment and management of cerebral dysfunction resulting from this potentially life-threatening disorder.